The VIRAGE2 trial is a small 6-patient feasibility study, not a pivotal efficacy trial, de-risking the dosing regimen for a future Phase 3 is a positive but early step. Monitor for enrollment updates and any interim safety data; the stock's $12M market cap means binary trial risk remains high. No financial data or guidance was provided, so the near-term catalyst is purely clinical.
Drug in focus
TOVX drug pipeline →VCN-01
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 2b completed; Phase 2a (VIRAGE2) authorized/enrolling; Phase 3 design aligned with FDA and EMA
- Time to market
- Likely 4-6 years if Phase 3 is successful, assuming the company secures funding/partnership to initiate a pivotal trial
- Next catalyst
- None dated
What to watchVCN-01 is the only meaningful asset at a ~$10M market-cap company. The positive VIRAGE Phase 2b data and FDA/EMA alignment on Phase 3 design are real positives, but the company has only ~$14M cash (runway into Q1 2027) and needs a partnership or dilutive financing to fund the pivotal trial. Watch for partnership/licensing announcements and VIRAGE2 interim data as the next catalysts, the stock is highly binary and prone to large swings.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 7 $0.2354entry
- T+1 · 4mo ago +1.02%α +1.33% · $0.2378
- T+5 · 4mo ago +2.00%α +1.45% · $0.2401
- T+20 · 4mo ago −5.40%α −6.73% · $0.2227
- T+60 · 7w ago −4.42%α −6.41% · $0.2250
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Theriva Biologics received regulatory authorization from the Spanish AEMPS to initiate the VIRAGE2 Phase 2a clinical trial, a 6-patient proof-of-concept study evaluating more frequent dosing (at least 3 doses) of oncolytic adenovirus VCN-01 in first-line metastatic pancreatic cancer. The trial builds on prior VIRAGE Phase 2b data where 2-dose VCN-01 showed significantly improved overall survival, progression-free survival, and duration of response versus 1-dose or chemotherapy alone. This is an early exploratory step toward a potential pivotal Phase 3 trial, but no financial data, guidance, or near-term revenue catalyst is provided.
Key Facts
- Spanish AEMPS authorized initiation of VIRAGE2 Phase 2a trial for VCN-01 in first-line metastatic pancreatic cancer
- VIRAGE2 is a 6-patient, single-arm, open-label, proof-of-concept trial evaluating at least 3 doses of VCN-01 given 2 months apart with gemcitabine/nab-paclitaxel
- Prior VIRAGE Phase 2b (112 patients) showed 2-dose VCN-01 significantly improved overall survival, progression-free survival, and duration of response vs 1-dose or chemotherapy alone
- EMA and FDA recognized improved survival with 2-dose VCN-01 and suggested more frequent dosing could improve outcomes
- VIRAGE2 results will inform dosing regimen for a potential future pivotal Phase 3 trial
- No financial data, guidance, or revenue figures were provided in this filing
Financial Impact
No financial data or guidance provided; this is a clinical trial authorization with no revenue or cost figures disclosed
Risk Factors
- VIRAGE2 is a 6-patient single-arm study not powered for efficacy, positive safety/tolerability data is needed before a Phase 3 can be designed
- Company has a $12M market cap with no disclosed revenue or financing; clinical-stage biotech carries high dilution and cash-burn risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-080962 |
| Document: tm2619846d1_ex99-1.htm | 0001104659-26-080962 |
| Document: 0001104659-26-080962-index-headers.html | 0001104659-26-080962 |
| Document: 0001104659-26-080962-index.html | 0001104659-26-080962 |
| Document: 0001104659-26-080962.txt | 0001104659-26-080962 |
Track record
11 reports on TOVX
2 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +17.39% at T+60 after the Aug 4, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.1600 to $0.1441 Now $0.1400 −12.50% ▼ −9.94% −9.57% vs SPY
- Nov 2, 202614d ago 8-K Neutral 5/10 Entry $0.1820 to $0.1900 Now $0.1400 −23.08% ▲ +4.40% +2.74% vs SPY
- Oct 20, 202627d ago DEF 14A Bearish 5/10 Entry $0.1966 to $0.1900 Now $0.1400 +28.79% ▲ +3.36% +2.18% vs SPY
- Aug 11, 202613w ago 8-K Neutral 4/10 No price data
- Aug 11, 202613w ago Press Release Neutral 5/10 Entry $0.2300 to $0.2400 Now $0.1400 −39.13% ▲ +4.35% +4.10% vs SPY
- Aug 4, 202614w ago 8-K Bearish 4/10 Entry $0.2300 to $0.2251 Now $0.1400 +39.13% ▲ +2.13% +1.93% vs SPY
- Jul 7, 202618w ago 8-K Bullish 5/10 Viewing Entry $0.2354 to $0.2378 Now $0.1400 −40.53% ▲ +1.02% +1.33% vs SPY
- Jun 11, 202622w ago Press Release Bullish 7/10 Entry $0.3070 to $0.3038 Now $0.1400 −54.40% ▼ −1.04% −1.58% vs SPY
- Apr 17, 202630w ago 8-K Bullish 7/10 Entry $0.4100 to $0.3400 Now $0.1400 −65.85% ▼ −17.07% −16.42% vs SPY
- Mar 12, 202635w ago 8-K Mixed 6/10 Entry $0.1800 to $0.1800 Now $0.1400 −22.22% · 0.00% +0.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers